YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock dual…
IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a video session lasti…
Earnings Call Insights: Castle Biosciences (CSTL) Q2 2026 MANAGEMENT VIEW * "What a great quarter." (Founder, CEO, President & Director Derek Maetzold) "We delivered revenue of $103.5 million, 20% growth compared to the second quarter of 2…
Key Points Interested in Castle Biosciences, Inc.? Here are five stocks we like better. Castle Biosciences reported strong Q2 growth, with revenue rising 20% year over year to $103.5 million. The company raised its 2026 revenue outlook to…
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring…
Castle Biosciences, Inc. Q1 2026 Earnings Call Summary - Moby Operational Performance and Strategic Drivers Revenue growth of 42% (excluding SCC and ID Genetics) was primarily driven by double-digit volume increases in core DecisionDx-Mela…
Castle Biosciences logo Key Points Q1 revenue was $83.7 million with core test report volumes up ~36% year‑over‑year, and management raised full‑year 2026 revenue guidance to $345–$355 million. DecisionDx‑Melanoma delivered 10,021 reports…
Alkermes plc ALKS reported a loss of 40 cents per share for the first quarter of 2026, which was narrower than the Zacks Consensus Estimate of a loss of 57 cents. The company had recorded earnings of 13 cents per share in the year-ago quar…
Ocugen OCGN incurred a loss of 6 cents per share in the first quarter of 2026, wider than the Zacks Consensus Estimate as well as the year-ago loss of 5 cents. Ocugen’s total revenues rose 3.5% year over year to $1.5 million in the first q…
Editas Medicine EDIT incurred a loss of 26 cents per share in the first quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had reported a loss of 43 cents per share in the year-ago quarter. Loss…
Repligen Corporation RGEN reported first-quarter 2026 adjusted earnings per share of 48 cents, which beat the Zacks Consensus Estimate of 38 cents. In the year-ago quarter, the company reported adjusted earnings of 39 cents per share. Tota…
Jazz Pharmaceuticals JAZZ reported first-quarter 2026 adjusted earnings per share (EPS) of $6.34, which beat the Zacks Consensus Estimate of $4.67. In the year-ago quarter, the company posted EPS of $1.68, which was significantly impacted…
BioMarin Pharmaceutical BMRN reported first-quarter 2026 adjusted earnings per share of 76 cents, missing the Zacks Consensus Estimate of 94 cents. However, earnings declined 33% year over year. This was largely due to a $31 million charge…
Krystal Biotech KRYS reported first-quarter 2026 earnings per share (EPS) of $1.83, which surpassed the Zacks Consensus Estimate of $1.45. The reported EPS was up from $1.20 in the year-ago quarter. Revenues of $116.4 million rose 32% year…
Axsome Therapeutics AXSM incurred a loss of $1.26 per share in the first quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 85 cents. The company had reported a loss of $1.22 per share in the year-ago quarter. Axsome’s t…
CRISPR Therapeutics CRSP reported a first-quarter 2026 loss of $1.28 per share, wider than the Zacks Consensus Estimate of a loss of $1.14. The company had incurred a loss of $1.58 in the year-ago quarter. Total revenues were $1.46 million…
Summit Therapeutics SMMT reported first-quarter 2026 loss per share of 24 cents, narrower than the Zacks Consensus Estimate of a loss of 33 cents. In the year-ago period, the company had incurred a loss of 9 cents per share. The company cu…
Kymera Therapeutics, Inc. KYMR posted a first-quarter 2026 loss of 71 cents per share, narrower than the Zacks Consensus Estimate of a loss of 89 cents. In the year-ago quarter, the company reported a loss of 82 cents per share. The compan…
Agios Pharmaceuticals AGIO reported a loss of $1.69 per share for the first quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of $1.81. In the year-ago quarter, the company had incurred a loss of $1.55 per share. Total…
Amarin Corporation AMRN incurred an adjusted loss of 9 cents per share for the first quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of $1.04. The company had reported an adjusted loss of 45 cents per share in the yea…
Viking Therapeutics VKTX posted a first-quarter 2026 loss of $1.37 per share, wider than the Zacks Consensus Estimate of a loss of 95 cents. The company had incurred a loss of 41 cents per share in the year-ago quarter. Currently, Viking T…
Bausch Health Companies Inc. BHC reported mixed results for the first quarter of 2026. Adjusted earnings per share (EPS) of 78 cents missed the Zacks Consensus Estimate of 81 cents but were up from 59 cents recorded in the year-ago quarter…
AbbVie ABBV announced that it has submitted a regulatory filing to the FDA seeking approval for a new indication of its blockbuster immunology drug, Rinvoq (upadacitinib). The filing seeks approval for the drug to treat adults and adolesce…
Shares of CytomX Therapeutics CTMX soared 44.2% on Monday after the company reported positive phase I expansion data for its EpCAM-targeting PROBODY ADC, varsetatug masetecan (Varseta-M), in late-line metastatic colorectal cancer (CRC) fro…
AstraZeneca AZN announced that the European Commission (EC) has approved its blockbuster cancer drug Imfinzi (durvalumab) as a perioperative treatment for early gastric and gastroesophageal junction (GEJ) cancers. Imfinzi is approved in co…
Novartis NVS announced that the FDA approved a label expansion of psoriasis drug Cosentyx. The regulatory body approved the drug for treating pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), maki…
Shares of United Therapeutics UTHR have surged approximately 32% over the past six months, driven by strong commercial growth, a major clinical breakthrough and improved long-term growth visibility, which have significantly strengthened in…
Shares of Beam Therapeutics BEAM have surged 23% over the past six months, reflecting growing investor confidence in its base-editing gene therapy platform and progress across its clinical pipeline. Positive Clinical Progress Boosted Inves…
Johnson & Johnson JNJ announced that it has submitted a type II variation application to the European Medicines Agency (EMA) seeking approval for the expanded use of Tecvayli (teclistamab). The application seeks to expand Tecvayli’s label…
On February 17, 2026, Portolan Capital Management disclosed a buy of Baidu(NASDAQ:BIDU), adding 259,101 shares in the fourth quarter for an estimated $32.16 million based on quarterly average pricing. What happened According to a SEC filin…
Eli Lilly LLY and Incyte INCY announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending the approval of the expanded use of Olumiant (baricitinib…
Regeneron Pharmaceuticals REGN and its partner Sanofi SNY announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the expanded use of their…
Puma Biotechnology PBYI reported fourth-quarter 2025 adjusted earnings of 29 cents per share, beating the Zacks Consensus Estimate of 24 cents. In the year-ago quarter, the company had reported adjusted earnings of 43 cents per share. The…
TG Therapeutics TGTX reported earnings of 14 cents per share for the fourth quarter of 2025, which substantially missed the Zacks Consensus Estimate of 35 cents. The company had reported earnings of 15 cents per share in the year-ago quart…
Perrigo PRGO reported adjusted earnings per share (EPS) of 77 cents for the fourth quarter of 2025, which missed the Zacks Consensus Estimate of 80 cents. The reported figure decreased 17.2% year over year, primarily due to headwinds in it…
Intellia Therapeutics NTLA reported a fourth-quarter 2025 loss of 83 cents per share (including one-time expenses of change in fair value of investments), narrower than the Zacks Consensus Estimate of a loss of 99 cents. In the year-ago qu…